What Is the Impact of Mammalian Target of Rapamycin Inhibitors on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Affiliations

Comment

Evangelos Cholongitas. Transplantation. 2022.

. 2022 Mar 1;106(3):e189.

doi: 10.1097/TP.0000000000003980.

¹ First Department of Internal Medicine, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Greece.

No abstract available

Comment on

Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials.
Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, Nevens F, Suh KS, Fischer L, Jin Joo D, Fung J, Joh JW, Kaido T, Grant D, Meier M, Rauer B, Sips C, Kaneko S, Levy G. Lee SG, et al. Transplantation. 2021 Jul 1;105(7):1564-1575. doi: 10.1097/TP.0000000000003394. Transplantation. 2021. PMID: 33741847 Free PMC article.

1. Lee SG, Jeng LB, Saliba F, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation. 2021;105:1564–1575.
1. Cholongitas E, Mamou C, Rodríguez-Castro KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039–1049.
1. Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125.
1. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59:1193–1199.
1. Cholongitas E, Antoniadis N, Goulis I, et al. Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2019;51:450–453.